Search

Supplemental material, sj-docx-1-cjk-10.1177_20543581231158067 for Long-Term Outcomes for Living Kidney Donors With Early Guideline-Concordant Follow-up Care: A Retrospective Cohort Study by Anisha Dhalla, Anita Lloyd, Krista L. Lentine, Amit X. Garg, Robert R. Quinn, Pietro Ravani, Scott W. Klarenbach, Brenda R. Hemmelgarn, Uchenna Ibelo and Ngan N. Lam in Canadian Journal of Kidney Health and Disease

Supplemental material, sj-docx-1-cjk-10.1177_20543581231165708 for Health Services Use and Outcomes for Hospital Admissions With a Major Cardiovascular Event Recorded in Health Care Administrative Data in Patients Receiving Maintenance Hemodialysis: A Retrospective Cohort Study by Ahmed A. Al-Jaishi, Nivethika Jeyakumar, Yuguang Kang, Sonali De Chickera, Stephanie N. Dixon, Bin Luo, Jessica Sontrop, Michael Walsh, Marcello Tonelli and Amit X. Garg in Canadian Journal of Kidney Health and Disease

Supplemental material, sj-docx-2-cjk-10.1177_20543581221150676 for Development and Validation of Patient Education Tools for Deprescribing in Patients on Hemodialysis by Thomas Hyunwoo Cho, Patrick C. K. Ng, Melissa J. Lefebvre, Arlene Desjarlais, Dennis McCann, Blair Waldvogel, Marcello Tonelli, Amit X. Garg, JoAnne Wilson, Monica Beaulieu, Judith Marin, Cali Orsulak, Melanie Talson, Monica Sharma, Jordanne Feldberg, Clara Bohm and Marisa Battistella in Canadian Journal of Kidney Health and Disease

Supplemental material, sj-docx-1-cjk-10.1177_20543581221150676 for Development and Validation of Patient Education Tools for Deprescribing in Patients on Hemodialysis by Thomas Hyunwoo Cho, Patrick C. K. Ng, Melissa J. Lefebvre, Arlene Desjarlais, Dennis McCann, Blair Waldvogel, Marcello Tonelli, Amit X. Garg, JoAnne Wilson, Monica Beaulieu, Judith Marin, Cali Orsulak, Melanie Talson, Monica Sharma, Jordanne Feldberg, Clara Bohm and Marisa Battistella in Canadian Journal of Kidney Health and Disease

Supplemental material, sj-docx-1-cjk-10.1177_20543581231169608 for Variation in Kidney Transplant Referral Across Chronic Kidney Disease Programs in Ontario, Canada by Seychelle Yohanna, Kyla L. Naylor, Bin Luo, Stephanie N. Dixon, Sarah E. Bota, S. Joseph Kim, Peter G. Blake, Lori Elliott, Rebecca Cooper, Gregory A. Knoll, Darin Treleaven, Carol Wang and Amit X. Garg in Canadian Journal of Kidney Health and Disease

Supplemental material, sj-docx-1-cjk-10.1177_20543581231154183 for Magnesium and Fracture Risk in the General Population and Patients Receiving Dialysis: A Narrative Review by Andrea C. Cowan, Kristin K. Clemens, Jessica M. Sontrop, Stephanie N. Dixon, Lauren Killin, Sierra Anderson, Rey R. Acedillo, Amit Bagga, Clara Bohm, Pierre Antoine Brown, Brenden Cote, Varun Dev, Claire Harris, Swapnil Hiremath, Mercedeh Kiaii, Eduardo Lacson Jr, Amber O. Molnar, Matthew J. Oliver, Malvinder S. Parmar, Jennifer M. McRae, Bharat Nathoo, Kathleen Quinn, Nikhil Shah, Samuel A. Silver, Daniel J. Tascona, Stephanie Thompson, Robert H. Ting, Marcello Tonelli, Hans Vorster, Davinder B. Wadehra, Ron Wald, Myles Wolf and Amit X. Garg in Canadian Journal of Kidney Health and Disease

Supplemental material, sj-docx-1-cjk-10.1177_20543581221130156 for KIdney aNd blooD prESsure ouTcomes in Childhood Cancer Survivors: Description of Clinical Research Protocol of the KINDEST-CCS Study by Adree Khondker, Michael Groff, Sophia Nunes, Carolyn Sun, Natasha Jawa, Jasmine Lee, Vedran Cockovski, Yasmine Hejri-Rad, Rahul Chanchlani, Adam Fleming, Amit Garg, Nivethika Jeyakumar, Abhijat Kitchlu, Asaf Lebel, Eric McArthur, Luc Mertens, Paul Nathan, Rulan Parekh, Serina Patel, Jason Pole, Raveena Ramphal, Tal Schechter, Mariana Silva, Samuel Silver, Lillian Sung, Ron Wald, Paul Gibson, Rachel Pearl, Laura Wheaton, Peter Wong, Kirby Kim and Michael Zappitelli in Canadian Journal of Kidney Health and Disease

Supplemental material, sj-docx-2-cjk-10.1177_20543581221129442 for The Living Kidney Donor Safety Study: Protocol of a Prospective Cohort Study by Amit X. Garg, Jennifer B. Arnold, Meaghan Cuerden, Christine Dipchand, Liane S. Feldman, John S. Gill, Martin Karpinski, Scott Klarenbach, Greg A. Knoll, Charmaine Lok, Matthew Miller, Mauricio Monroy-Cuadros, Christopher Nguan, G. V. Ramesh Prasad, Jessica M. Sontrop, Leroy Storsley and Neil Boudville in Canadian Journal of Kidney Health and Disease

Supplemental material, sj-docx-2-cjk-10.1177_20543581221084502 for Protocol for a Process Evaluation of the Quality Improvement Intervention to Enhance Access to Kidney Transplantation and Living Kidney Donation (EnAKT LKD) Cluster-Randomized Clinical Trial by Seychelle Yohanna, Mackenzie Wilson, Kyla L. Naylor, Amit X. Garg, Jessica M. Sontrop, Dmitri Belenko, Lori Elliott, Susan McKenzie, Sara Macanovic, Istvan Mucsi, Rachel Patzer, Irina Voronin, Iris Lui, Peter G. Blake, Amy D. Waterman, Darin Treleaven and Justin Presseau in Canadian Journal of Kidney Health and Disease

Supplemental material, sj-docx-1-cjk-10.1177_20543581221129442 for The Living Kidney Donor Safety Study: Protocol of a Prospective Cohort Study by Amit X. Garg, Jennifer B. Arnold, Meaghan Cuerden, Christine Dipchand, Liane S. Feldman, John S. Gill, Martin Karpinski, Scott Klarenbach, Greg A. Knoll, Charmaine Lok, Matthew Miller, Mauricio Monroy-Cuadros, Christopher Nguan, G. V. Ramesh Prasad, Jessica M. Sontrop, Leroy Storsley and Neil Boudville in Canadian Journal of Kidney Health and Disease

Supplemental material, sj-pdf-1-cjk-10.1177_20543581221131201 for Enhance Access to Kidney Transplantation and Living Kidney Donation (EnAKT LKD): Statistical Analysis Plan of a Registry-Based, Cluster-Randomized Clinical Trial by Stephanie N. Dixon, Kyla L. Naylor, Seychelle Yohanna, Susan McKenzie, Dmitri Belenko, Peter G Blake, Candice Coghlan, Rebecca Cooper, Lori Elliott, Leah Getchell, Vincent Ki, Istvan Mucsi, Gihad Nesrallah, Rachel E. Patzer, Justin Presseau, Marian Reich, Jessica M. Sontrop, Darin Treleaven, Amy D. Waterman, Jeffrey Zaltzman and Amit X. Garg in Canadian Journal of Kidney Health and Disease

Supplemental material, sj-docx-2-cjk-10.1177_20543581221111712 for Using Administrative Health Care Databases to Identify Patients With End-Stage Kidney Disease With No Recorded Contraindication to Receiving a Kidney Transplant by Carol Wang, Kyla L. Naylor, Bin Luo, Sarah E. Bota, Stephanie N. Dixon, Seychelle Yohanna, Darin Treleaven, Lori Elliott and Amit X. Garg in Canadian Journal of Kidney Health and Disease

Supplemental material, sj-docx-1-cjk-10.1177_20543581211069225 for Effect of a Perioperative Hypotension-Avoidance Strategy Versus a Hypertension-Avoidance Strategy on the Risk of Acute Kidney Injury: A Clinical Research Protocol for a Substudy of the POISE-3 Randomized Clinical Trial by Amit X. Garg, Meaghan Cuerden, Hector Aguado, Mohammed Amir, Emilie P. Belley-Cote, Keyur Bhatt, Bruce M. Biccard, Flavia K. Borges, Matthew Chan, David Conen, Emmanuelle Duceppe, Sergey Efremov, John Eikelboom, Edith Fleischmann, Landoni Giovanni, Peter Gross, Raja Jayaram, Mikhail Kirov, Ydo Kleinlugtenbelt, Andrea Kurz, Andre Lamy, Kate Leslie, Valery Likhvantsev, Vladimir Lomivorotov, Maura Marcucci, Maria Jos�� Mart��nez-Zapata, Michael McGillion, William McIntyre, Christian Meyhoff, Sandra Ofori, Thomas Painter, Pilar Paniagua, Chirag Parikh, Joel Parlow, Ameen Patel, Carisi Polanczyk, Toby Richards, Pavel Roshanov, Denis Schmartz, Daniel Sessler, Tim Short, Jessica M. Sontrop, Jessica Spence, Sadeesh Srinathan, David Stillo, Wojciech Szczeklik, Vikas Tandon, David Torres, Thomas Van Helder, Jessica Vincent, C. Y. Wang, Michael Wang, Richard Whitlock, Maria Wittmann, Denis Xavier and P. J. Devereaux in Canadian Journal of Kidney Health and Disease

Supplemental material, sj-docx-1-cjk-10.1177_20543581221084502 for Protocol for a Process Evaluation of the Quality Improvement Intervention to Enhance Access to Kidney Transplantation and Living Kidney Donation (EnAKT LKD) Cluster-Randomized Clinical Trial by Seychelle Yohanna, Mackenzie Wilson, Kyla L. Naylor, Amit X. Garg, Jessica M. Sontrop, Dmitri Belenko, Lori Elliott, Susan McKenzie, Sara Macanovic, Istvan Mucsi, Rachel Patzer, Irina Voronin, Iris Lui, Peter G. Blake, Amy D. Waterman, Darin Treleaven and Justin Presseau in Canadian Journal of Kidney Health and Disease

Supplemental material, sj-docx-4-cjk-10.1177_20543581221084502 for Protocol for a Process Evaluation of the Quality Improvement Intervention to Enhance Access to Kidney Transplantation and Living Kidney Donation (EnAKT LKD) Cluster-Randomized Clinical Trial by Seychelle Yohanna, Mackenzie Wilson, Kyla L. Naylor, Amit X. Garg, Jessica M. Sontrop, Dmitri Belenko, Lori Elliott, Susan McKenzie, Sara Macanovic, Istvan Mucsi, Rachel Patzer, Irina Voronin, Iris Lui, Peter G. Blake, Amy D. Waterman, Darin Treleaven and Justin Presseau in Canadian Journal of Kidney Health and Disease

Supplemental material, sj-docx-1-cjk-10.1177_20543581221111712 for Using Administrative Health Care Databases to Identify Patients With End-Stage Kidney Disease With No Recorded Contraindication to Receiving a Kidney Transplant by Carol Wang, Kyla L. Naylor, Bin Luo, Sarah E. Bota, Stephanie N. Dixon, Seychelle Yohanna, Darin Treleaven, Lori Elliott and Amit X. Garg in Canadian Journal of Kidney Health and Disease

Supplemental material, sj-docx-3-cjk-10.1177_20543581221084502 for Protocol for a Process Evaluation of the Quality Improvement Intervention to Enhance Access to Kidney Transplantation and Living Kidney Donation (EnAKT LKD) Cluster-Randomized Clinical Trial by Seychelle Yohanna, Mackenzie Wilson, Kyla L. Naylor, Amit X. Garg, Jessica M. Sontrop, Dmitri Belenko, Lori Elliott, Susan McKenzie, Sara Macanovic, Istvan Mucsi, Rachel Patzer, Irina Voronin, Iris Lui, Peter G. Blake, Amy D. Waterman, Darin Treleaven and Justin Presseau in Canadian Journal of Kidney Health and Disease

Supplemental material, sj-docx-1-cjk-10.1177_20543581211056234 for Comparison of All-Cause Mortality Between Canadian Kidney Transplant Recipients and Patients With Cancer: A Population-Based Cohort Study by Kyla L. Naylor, S. Joseph Kim, Eric McArthur, Amit X. Garg, Marlee Vinegar, Megan K. McCallum and Gregory A. Knoll in Canadian Journal of Kidney Health and Disease

Supplemental material, sj-pdf-1-cjk-10.1177_20543581211060926 for Risk Factors and Outcomes of Early Hospital Readmission in Canadian Kidney Transplant Recipients: A Population-Based Multi-Center Cohort Study by Kyla L. Naylor, Gregory A. Knoll, Justin Slater, Eric McArthur, Amit X. Garg, Ngan N. Lam, Britney Le, Alvin H. Li, Megan K. McCallum, Marlee Vinegar and S. Joseph Kim in Canadian Journal of Kidney Health and Disease

Supplemental material, sj-pdf-1-cjk-10.1177_2054358120985376 for Outcomes of an Inpatient Dialysis Start in Patients With Kidney Graft Failure: A Population-Based Multicentre Cohort Study by Kyla L. Naylor, Gregory A. Knoll, Eric McArthur, Amit X. Garg, Ngan N. Lam, Bonnie Field, Leah E. Getchell, Emma Hahn and S. Joseph Kim in Canadian Journal of Kidney Health and Disease

BACKGROUND: Perioperative corticosteroid use may reduce acute kidney injury. We sought to test whether methylprednisolone reduces the risk of acute kidney injury after cardiac surgery. METHODS: We conducted a prespecified substudy of a randomized controlled trial involving patients undergoing cardiac surgery with cardiopulmonary bypass (2007-2014); patients were recruited from 79 centres in 18 countries. Eligibility criteria included a moderate-to-high risk of perioperative death based on a preoperative score of 6 or greater on the European System for Cardiac Operative Risk Evaluation I. Patients (n = 7286) were randomly assigned (1:1) to receive intravenous methylprednisolone (250 mg at anesthetic induction and 250 mg at initiation of cardiopulmonary bypass) or placebo. Patients, caregivers, data collectors and outcome adjudicators were unaware of the assigned intervention. The primary outcome was postoperative acute kidney injury, defined as an increase in the serum creatinine concentration (from the preoperative value) of 0.3 mg/dL or greater (≥ 26.5 μmol/L) or 50% or greater in the 14-day period after surgery, or use of dialysis within 30 days after surgery. RESULTS: Acute kidney injury occurred in 1479/3647 patients (40.6%) in the methylprednisolone group and in 1426/3639 patients (39.2%) in the placebo group (adjusted relative risk 1.04, 95% confidence interval 0.96 to 1.11). Results were consistent across several definitions of acute kidney injury and in patients with preoperative chronic kidney disease. INTERPRETATION: Intraoperative corticosteroid use did not reduce the risk of acute kidney injury in patients with a moderate-to-high risk of perioperative death who had cardiac surgery with cardiopulmonary bypass. Our results do not support the prophylactic use of steroids during cardiopulmonary bypass surgery. Trial registration: ClinicalTrials.gov, no. NCT00427388. ispartof: CANADIAN MEDICAL ASSOCIATION JOURNAL vol:191 issue:9 pages:E247-E256 ispartof: location:Canada status: published

Purpose To characterize the pharmacokinetics (PK) of pertuzumab and trastuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer in the randomized, double-blind, phase III JACOB study (NCT01774786), and to evaluate the appropriateness of the pertuzumab regimen in these patients. Methods Patients received 840 mg intravenous pertuzumab or placebo plus trastuzumab q3w and chemotherapy. Pertuzumab and trastuzumab were administered until disease progression or unacceptable toxicity. Chemotherapy was administered for up to six cycles or disease progression or unacceptable toxicity. Serum concentrations of pertuzumab and trastuzumab were measured. Pertuzumab PK was characterized across treatment cycles. The impact of anti-drug antibodies (ADAs) on pertuzumab PK and the impact of pertuzumab on trastuzumab PK were assessed. An exploratory exposure–efficacy analysis was also conducted. Results In total, 374 patients in the pertuzumab arm had evaluable PK data. The mean observed pertuzumab steady-state serum trough (minimum) concentration (Cmin,ss) ± standard deviation was 114 ± 51.8 μg/mL. The target pertuzumab Cmin,ss of ≥ 20 μg/mL was reached in 99.3% of patients at Cycle 5 (steady state) and beyond. Greater than 90% of patients were above the PK target right after the first pertuzumab dose. There was no apparent impact of ADAs on pertuzumab PK nor of pertuzumab on trastuzumab PK. There were no differences in overall survival across Cycle 1 pertuzumab (Cmin) or Cycle 5 pertuzumab (Cmin,ss) exposure quartiles. Conclusions Pertuzumab exposure in JACOB was consistent with prior studies in advanced gastric cancer and breast cancer. The 840 mg q3w dose allowed the majority of patients in JACOB to achieve target pertuzumab concentrations and appears to be an appropriate dose selection. Electronic supplementary material The online version of this article (10.1007/s00280-019-03871-w) contains supplementary material, which is available to authorized users.

Supplemental material, RTx_Macrolides_-_Appendix_-_20181231 for Outcomes Following Macrolide Use in Kidney Transplant Recipients by Rachel Jeong, Robert R. Quinn, Krista L. Lentine, Anita Lloyd, Pietro Ravani, Brenda Hemmelgarn, Branko Braam, Amit X. Garg, Kevin Wen, Anita Wong-Chan, Sita Gourishankar and Ngan N. Lam in Canadian Journal of Kidney Health and Disease

Supplemental Material, AppendixA_Ear_PsO_2018 for Results of a Survey of the National Psoriasis Foundation Medical Board on the Management of Ear Psoriasis by Amy Blake, Clinton Enos, April W. Armstrong, Amit Garg, Alice Gottlieb, John Koo, Nehal Mehta, Ronald Prussick, Caitriona Ryan, Sergio Schwartzman, Michael Siegel, Jashin J. Wu, Barry Strasnick and Abby S. Van Voorhees in Journal of Psoriasis and Psoriatic Arthritis

Neuroendocrine tumors (NETs) have historically been subcategorized according to histologic features and the site of anatomic origin. Here, we characterize the genomic alterations in patients enrolled in 3 phase 3 clinical trials of NET of different anatomic origins and assessed the potential correlation with clinical outcomes. Whole-exome and targeted panel sequencing was used to characterize 225 NET samples collected in the RADIANT series of clinical trials. Genomic profiling of NET was analyzed along with nongenomic biomarker data on tumor grade and circulating chromogranin A (CgA) and neuron specific enolase (NSE) levels from these patients enrolled in clinical trials. Our results highlight recurrent large-scale chromosomal alterations as a common theme among NET. Although the specific pattern of chromosomal alterations differed between tumor subtypes, the evidence for generalized chromosomal instability (CIN) was observed across all primary sites of NET. In pancreatic NET, although the P-value was not significant, higher CIN suggests a trend towards longer survival (HR, 0.55, P=0.077); whereas in the gastrointestinal NET, lower CIN was associated with longer survival (HR, 0.44, P=0.0006). Our multivariate analyses demonstrated that when combined with other clinical data among patients with progressive advanced NETs, chromosomal level alteration adds important prognostic information. Large-scale CIN is a common feature of NET, and specific patterns of chromosomal gain and loss appeared to have independent prognostic value in NET subtypes. However, whether CIN in general has clinical significance in NET requires validation in larger patient cohort and warrants further mechanistic studies. ispartof: ENDOCRINE-RELATED CANCER vol:26 issue:4 pages:391-403 ispartof: location:England status: published

Supplemental material, Appendix_2018_06_05 for Comparing Five Comorbidity Indices to Predict Mortality in Chronic Kidney Disease: A Retrospective Cohort Study by Eric McArthur, Sarah E. Bota, Manish M. Sood, Gihad E. Nesrallah, S Joseph Kim, Amit X. Garg and Stephanie N. Dixon in Canadian Journal of Kidney Health and Disease

The Chronic Kidney Disease (CKD) Prognosis Consortium is a collaborative author of the above-mentioned article. The CKD Prognosis Consortium investigators/collaborators are as follows: • African American Study of Kidney Disease and Hypertension (AASK): Brad Astor, Lawrence J. Appel; Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT): Adeera Levin, Mila Tang, Ognjenka Djurdjev; Cleveland Clinic CKD Registry Study (CCF): Sankar D. Navaneethan, Stacey E. Jolly, Jesse D. Schold, Joseph V. Nally Jr.; Chronic Renal Impairment in Birmingham (CRIB): David C. Wheeler, Jonathan Emberson, John Townend, Martin Landray; Chronic Renal Insufficiency Cohort Study (CRIC): Harold I. Feldman, Chi-yuan Hsu, James P. Lash, Lawrence J. Appel; Chronic Renal Insufficiency Standards Implementation Study (CRISIS): Philip A. Kalra, James P. Ritchie, Raman Maharajan, Rachel J. Middleton, Donal J. O'Donoghue; German Chronic Kidney Disease Study (GCKD): Kai-Uwe Eckardt, Markus P. Schneider, Anna Kottgen, Florian Kronenberg, Barbara Barthlein; Geisinger Health System: Alex R. Chang, Jamie A. Green, H. Lester Kirchner, Kevin Ho; Grampian Laboratory Outcomes, Morbidity and Mortality Studies – 2 (GLOMMS2): Angharad Marks, Corri Black, Gordon J. Prescott, Nick Fluck; Gonryo Study: Masaaki Nakayama, Mariko Miyazaki, Tae Yamamoto, Gen Yamada; Hong Kong CKD Studies: Angela Yee-Moon Wang, Sharon Cheung, Sharon Wong, Jessie Chu, Henry Wu; Ontario Institute for Clinical Evaluative Sciences, Provincial Kidney, Dialysis and Transplantation program (ICES KDT): Amit X. Garg, Eric McArthur, Danielle M. Nash; Maccabi Health System: Varda Shalev, Gabriel Chodick; Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner (MASTERPLAN): Peter J. Blankestijn, Jack F.M. Wetzels, Arjan D. van Zuilen, Jan A. van den Brand; Modification of Diet in Renal Disease Study (MDRD): Andrew S. Levey, Lesley A. Inker, Mark J. Sarnak, Hocine Tighiouart; Nanjing CKD Network Cohort Study (Nanjing CKD): Haitao Zhang; NephroTest Study (NephroTest): Benedicte Stengel, Marie Metzger, Martin Flamant, Pascal Houillier, Jean-Philippe Haymann; National Renal Healthcare Program – Uruguay (NRHP-URU): Pablo G. Rios, Nelson Mazzuchi, Liliana Gadola, Veronica Lamadrid, Laura Sola; New Zealand Diabetes Cohort Study (NZDCS): John F. Collins, C. Raina Elley, Timothy Kenealy; Parcours de Soins des Personnes Agees (PSPA): Olivier Moranne, Cecile Couchoud, Cecile Vigneau; Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease (PSP CKD): Nigel J. Brunskill, Rupert W. Major, David Shepherd, James F. Medcalf; Racial and Cardiovascular Risk Anomalies in CKD Cohort (RCAV): Csaba P. Kovesdy, Kamyar Kalantar-Zadeh, Miklos Z. Molnar, Keiichi Sumida, Praveen K. Potukuchi; Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL): Hiddo J.L. Heerspink, Dick de Zeeuw, Barry Brenner; Stockholm CREAtinine Measurements Cohort (SCREAM): Juan Jesus Carrero, Alessandro Gasparini, Abdul Rashid Qureshi, Carl-Gustaf Elinder; Second Manifestations of ARTerial Disease Study (SMART): Frank L.J. Visseren, Yolanda van der Graaf; Swedish Renal Registry CKD Cohort (SRR CKD): Marie Evans, Maria Stendahl, Staffan Schon, Marten Segelmark, Karl-Goran Prutz; Sunnybrook Cohort: David M. Naimark, Navdeep Tangri; West of Scotland CKD Study: Patrick B. Mark, Jamie P. Traynor, Colin C. Geddes, Peter C. Thomson.• CKD Prognosis Consortium Steering Committee: Alex R. Chang, Josef Coresh (Chair), Ron T. Gansevoort, Morgan E. Grams, Anna Kottgen, Andrew S. Levey, Kunihiro Matsushita, Mark Woodward, Luxia Zhang.• CKD Prognosis Consortium Data Coordinating Center: Shoshana H. Ballew (Assistant Project Director), Jingsha Chen (Programmer), Josef Coresh (Principal Investigator), Morgan E. Grams (Director of Nephrology Initiatives), Lucia Kwak (Programmer), Kunihiro Matsushita (Director), Yingying Sang (Lead Programmer), Aditya Surapaneni (Programmer), Mark Woodward (Senior Statistician).• Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference on Prognosis and Optimal Management of Patients with Advanced CKD: Kai-Uwe Eckardt (Conference Co-Chair), Brenda R. Hemmelgarn (Conference Co-Chair), David C. Wheeler (KDIGO Co-Chair), Wolfgang C. Winkelmayer (KDIGO Co-Chair), John Davis (CEO), Danielle Green (Managing Director), Michael Cheung (Chief Scientific Officer), Tanya Green (Communications Director), Melissa McMahan (Programs Director).

Trimethylamine-N-oxide (TMAO) is a recently identified predictor of cardiovascular and chronic kidney disease. TMAO is primarily generated through gut-microbiome mediated conversion of dietary choline and carnitine to TMA, which is converted to TMAO by hepatic flavin monooxygenase 3 (FMO3) and subsequently undergoes renal elimination. We investigated the role of uptake and efflux drug transporters in TMAO disposition in vitro and in vivo. After screening a large array of uptake transporters, we show organic cation transporter 2 (OCT2) is the key transporter for TMAO cellular uptake. In Oct1/2 knockout mice, we observed increased plasma TMAO levels with reduced renal retention, suggesting the importance of Oct2 in facilitating the uptake of TMAO into renal tubular cells in vivo. Multiple transporters of the ATP-binding cassette (ABC) family, including ABCG2 (BCRP) and ABCB1 (MDR1), were capable of TMAO efflux. In human subjects, clinical, dietary, and pharmacogenetic covariates were evaluated for contribution to TMAO levels in a cohort of dyslipidemic patients (n = 405). Interestingly, genetic variation in ABCG2, but not other transporters, appeared to play a role in modulating TMAO exposure.

IMPORTANCE Little is known about the relationship between perioperative high-sensitivity troponin T (hsTnT) measurements and 30-day mortality and myocardial injury after noncardiac surgery (MINS). OBJECTIVE To determine the association between perioperative hsTnT measurements and 30-day mortality and potential diagnostic criteria for MINS (ie, myocardial injury due to ischemia associated with 30-day mortality). DESIGN, SETTING, AND PARTICIPANTS Prospective cohort study of patients aged 45 years or older who underwent inpatient noncardiac surgery and had a postoperative hsTnT measurement. Starting in October 2008, participants were recruited at 23 centers in 13 countries; follow-up finished in December 2013. EXPOSURES Patients had hsTnT measurements 6 to 12 hours after surgery and daily for 3 days; 40.4% had a preoperative hsTnT measurement. MAIN OUTCOMES AND MEASURES A modified Mazumdar approach (an iterative process) was used to determine if there were hsTnT thresholds associated with risk of death and had an adjusted hazard ratio (HR) of 3.0 or higher and a risk of 30-day mortality of 3% or higher. To determine potential diagnostic criteria for MINS, regression analyses ascertained if postoperative hsTnT elevations required an ischemic feature (eg, ischemic symptom or electrocardiography finding) to be associated with 30-day mortality. RESULTS Among 21 842 participants, the mean age was 63.1 (SD, 10.7) years and 49.1% were female. Death within 30 days after surgery occurred in 266 patients (1.2%; 95% CI, 1.1%-1.4%). Multivariable analysis demonstrated that compared with the reference group (peak hsTnT = 5 ng/L or hsTnT >= 65 ng/L) without an ischemic feature was associated with 30-day mortality (adjusted HR, 3.20; 95% CI, 2.37-4.32). Among the 3904 patients (17.9%; 95% CI, 17.4%-18.4%) with MINS, 3633 (93.1%; 95% CI, 92.2%-93.8%) did not experience an ischemic symptom. CONCLUSIONS AND RELEVANCE Among patients undergoing noncardiac surgery, peak postoperative hsTnT during the first 3 days after surgery was significantly associated with 30-day mortality. Elevated postoperative hsTnT without an ischemic feature was also associated with 30-day mortality.

Supplemental material, sj-pdf-1-cjk-10.1177_2054358120972830 for Complications in Patients With Autosomal Dominant Polycystic Kidney Disease Undergoing Ureteroscopy: A Cohort Study by Vinusha Kalatharan, Blayne Welk, Danielle M. Nash, Eric McArthur, Justin Slater, Sisira Sarma, York Pei and Amit X. Garg in Canadian Journal of Kidney Health and Disease

Supplemental material, Appendix_4_-_residual_plots for Can Split Renal Volume Assessment by Computed Tomography Replace Nuclear Split Renal Function in Living Kidney Donor Evaluations? A Systematic Review and Meta-Analysis by Steven Habbous, Carlos Garcia-Ochoa, Gary Brahm, Chris Nguan and Amit X. Garg in Canadian Journal of Kidney Health and Disease

Supplemental material, Supplementary_Material_CJKHD for Ethical Issues in the Design and Conduct of Pragmatic Cluster Randomized Trials in Hemodialysis Care: An Interview Study With Key Stakeholders by Stuart G. Nicholls, Kelly Carroll, Charles Weijer, Cory E. Goldstein, Jamie Brehaut, Manish M. Sood, Ahmed Al-Jaishi, Erika Basile, Jeremy M. Grimshaw, Amit X. Garg and Monica Taljaard in Canadian Journal of Kidney Health and Disease

Supplemental material, SUPPLEMENTARY_MATERIALS_1 for Efficacy and Safety of Surgical Kidney Stone Interventions in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review by Vinusha Kalatharan, Racquel Jandoc, Gary Grewal, Danielle M. Nash, Blayne Welk, Sisira Sarma, York Pei and Amit X. Garg in Canadian Journal of Kidney Health and Disease

Supplemental material, Supplementary_Materials for Predicting 3-Year Survival in Patients Receiving Maintenance Dialysis: An External Validation of iChoose Kidney in Ontario, Canada by Vivian S. Tan, Amit X. Garg, Eric McArthur, Rachel E. Patzer, Jennifer Gander, Pavel Roshanov, S. Joseph Kim, Greg A. Knoll, Seychelle Yohanna, Megan K. McCallum and Kyla L. Naylor in Canadian Journal of Kidney Health and Disease

Supplemental material, SUPPLEMENTARY_MATERIALS_1 for Efficacy and Safety of Surgical Kidney Stone Interventions in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review by Vinusha Kalatharan, Racquel Jandoc, Gary Grewal, Danielle M. Nash, Blayne Welk, Sisira Sarma, York Pei and Amit X. Garg in Canadian Journal of Kidney Health and Disease

Supplemental material, sj-pdf-1-cjk-10.1177_20543581211032818 for Patient Partner Perspectives Regarding Ethically and Clinically Important Aspects of Trial Design in Pragmatic Cluster Randomized Trials for Hemodialysis by Stuart G. Nicholls, Kelly Carroll, Cory E. Goldstein, Jamie C. Brehaut, Charles Weijer, Merrick Zwarenstein, Stephanie Dixon, Jeremy M. Grimshaw, Amit X. Garg and Monica Taljaard in Canadian Journal of Kidney Health and Disease

Supplemental material, Appendix_2_-_PRISMA_-_CT_SRV_and_SRF.docx_1 for Can Split Renal Volume Assessment by Computed Tomography Replace Nuclear Split Renal Function in Living Kidney Donor Evaluations? A Systematic Review and Meta-Analysis by Steven Habbous, Carlos Garcia-Ochoa, Gary Brahm, Chris Nguan and Amit X. Garg in Canadian Journal of Kidney Health and Disease

Supplemental material, CJKHD-20-0099.R1_Translation for Development and Validation of Nine Deprescribing Algorithms for Patients on Hemodialysis to Decrease Polypharmacy by Melissa J. Lefebvre, Patrick C. K. Ng, Arlene Desjarlais, Dennis McCann, Blair Waldvogel, Marcello Tonelli, Amit X. Garg, Jo-Anne Wilson, Monica Beaulieu, Judith Marin, Cali Orsulak, Anita Lloyd, Caitlin McIntyre, Jordanne Feldberg, Clara Bohm and Marisa Battistella in Canadian Journal of Kidney Health and Disease

Supplemental material, sj-pdf-1-cjk-10.1177_20543581211000227 for Risk of Hospital Encounters With Kidney Stones in Autosomal Dominant Polycystic Kidney Disease: A Cohort Study by Vinusha Kalatharan, Blayne Welk, Danielle M. Nash, Stephanie N. Dixon, Justin Slater, York Pei, Sisira Sarma and Amit X. Garg in Canadian Journal of Kidney Health and Disease

Supplemental material, Varghese-CJKHD-20-0105-R1_Appendix_I_and_II_Revised_Copy for A Higher Concentration of Dialysate Magnesium to Reduce the Frequency of Muscle Cramps: A Narrative Review by Akshay Varghese, Eduardo Lacson, Jessica M. Sontrop, Rey R. Acedillo, Ahmed A. Al-Jaishi, Sierra Anderson, Amit Bagga, Katie L. Bain, Laura L. Bennett, Clara Bohm, Pierre A. Brown, Christopher T. Chan, Brenden Cote, Varun Dev, Bonnie Field, Claire Harris, Shasikara Kalatharan, Mercedeh Kiaii, Amber O. Molnar, Matthew J. Oliver, Malvinder S. Parmar, Melissa Schorr, Nikhil Shah, Samuel A. Silver, D. Michael Smith, Manish M. Sood, Irina St. Louis, Karthik K. Tennankore, Stephanie Thompson, Marcello Tonelli, Hans Vorster, Blair Waldvogel, James Zacharias and Amit X. Garg in Canadian Journal of Kidney Health and Disease

Supplemental material, Appendix_1 for Can Split Renal Volume Assessment by Computed Tomography Replace Nuclear Split Renal Function in Living Kidney Donor Evaluations? A Systematic Review and Meta-Analysis by Steven Habbous, Carlos Garcia-Ochoa, Gary Brahm, Chris Nguan and Amit X. Garg in Canadian Journal of Kidney Health and Disease

Supplemental material, supplemental_material-_R1Black for Thiazide Diuretic Dose and Risk of Kidney Stones in Older Adults: A Retrospective Cohort Study by R. Todd Alexander, Eric McArthur, Racquel Jandoc, Blayne Welk, Daniel G. Fuster, Amit X. Garg and Robert R. Quinn in Canadian Journal of Kidney Health and Disease

Supplemental material, SupplementaryMaterials_PrevalenceOfStone_CJKHD for Stone Prevalence in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis by Vinusha Kalatharan, Gary Grewal, Danielle M Nash, Blayne Welk, Sisira Sarma, York Pei and Amit X. Garg in Canadian Journal of Kidney Health and Disease

Supplemental material, Appendices for Major Outcomes With Personalized Dialysate TEMPerature (MyTEMP): Rationale and Design of a Pragmatic, Registry-Based, Cluster Randomized Controlled Trial by Ahmed A. Al-Jaishi, Christopher W. McIntyre, Jessica M. Sontrop, Stephanie N. Dixon, Sierra Anderson, Amit Bagga, Derek Benjamin, David Berry, Peter G. Blake, Laura Chambers, Patricia C. K. Chan, Nicole Delbrouck, P. J. Devereaux, Luis F. Ferreira-Divino, Richard Goluch, Laura Gregor, Jeremy M. Grimshaw, Garth Hanson, Eduard Iliescu, Arsh K. Jain, Charmaine E. Lok, Reem A. Mustafa, Bharat Nathoo, Gihad E. Nesrallah, Matthew J. Oliver, Sanjay Pandeya, Malvinder S. Parmar, David Perkins, Justin Presseau, Eli Rabin, Joanna Sasal, Tanya Shulman, Manish M. Sood, Andrew Steele, Paul Tam, Daniel Tascona, Davinder Wadehra, Ron Wald, Michael Walsh, Paul Watson, Walter Wodchis, Phillip Zager, Merrick Zwarenstein and Amit X. Garg in Canadian Journal of Kidney Health and Disease

Supplemental material, Appendix_3_-_individual-level_data_-__donors_only for Can Split Renal Volume Assessment by Computed Tomography Replace Nuclear Split Renal Function in Living Kidney Donor Evaluations? A Systematic Review and Meta-Analysis by Steven Habbous, Carlos Garcia-Ochoa, Gary Brahm, Chris Nguan and Amit X. Garg in Canadian Journal of Kidney Health and Disease

Supplemental material, suppl_file/Polypharm_Supplemental for A Province-wide, Cross-sectional Study of Demographics and Medication Use of Patients in Hemodialysis Units Across Ontario by Marisa Battistella, Racquel Jandoc, Jeremy Y. Ng, Eric McArthur and Amit X. Garg in Canadian Journal of Kidney Health and Disease

Supplemental material, sj-pdf-1-cjk-10.1177_20543581211032818 for Patient Partner Perspectives Regarding Ethically and Clinically Important Aspects of Trial Design in Pragmatic Cluster Randomized Trials for Hemodialysis by Stuart G. Nicholls, Kelly Carroll, Cory E. Goldstein, Jamie C. Brehaut, Charles Weijer, Merrick Zwarenstein, Stephanie Dixon, Jeremy M. Grimshaw, Amit X. Garg and Monica Taljaard in Canadian Journal of Kidney Health and Disease